Cargando…

Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?

OBJECTIVE: To investigate whether visual disability which is known to accumulate by poor recovery from optic neuritis (ON) attacks can be lessened by early treatment, we investigated whether the time from symptom onset to high-dose IV methylprednisolone (IVMP) affected visual recovery. METHODS: A re...

Descripción completa

Detalles Bibliográficos
Autores principales: Stiebel-Kalish, Hadas, Hellmann, Mark Andrew, Mimouni, Michael, Paul, Friedemann, Bialer, Omer, Bach, Michael, Lotan, Itay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624092/
https://www.ncbi.nlm.nih.gov/pubmed/31355308
http://dx.doi.org/10.1212/NXI.0000000000000572
_version_ 1783434203208089600
author Stiebel-Kalish, Hadas
Hellmann, Mark Andrew
Mimouni, Michael
Paul, Friedemann
Bialer, Omer
Bach, Michael
Lotan, Itay
author_facet Stiebel-Kalish, Hadas
Hellmann, Mark Andrew
Mimouni, Michael
Paul, Friedemann
Bialer, Omer
Bach, Michael
Lotan, Itay
author_sort Stiebel-Kalish, Hadas
collection PubMed
description OBJECTIVE: To investigate whether visual disability which is known to accumulate by poor recovery from optic neuritis (ON) attacks can be lessened by early treatment, we investigated whether the time from symptom onset to high-dose IV methylprednisolone (IVMP) affected visual recovery. METHODS: A retrospective study was performed in a consecutive cohort of patients following their first aquaporin-4 (AQP4)-IgG or myelin oligodendrocyte glycoprotein (MOG)-IgG-ON. Best-corrected visual acuity (BCVA) in ON eyes at 3 months (BCVA3mo) was correlated with time to IVMP (days). In cases of bilateral ON, 1 eye was randomly selected. RESULTS: A total of 29 of 37 patients had ON (27 AQP4-seropositive neuromyelitis optica spectrum disorder [NMOSD] and 9 MOG-IgG-ON), 2 of whom refused treatment. Of the 27 patients included, 10 presented later than 7 days from onset. The median BCVA3mo of patients treated >7 days was 20/100 (interquartile range 20/100–20/200). Patients treated >7 days had an OR of 5.50 (95% CI 0.88–34.46, p = 0.051) of failure to regain 0.0 logMAR vision (20/20) and an OR of 10.0 (95% CI 1.39–71.9) of failure to regain 0.2 logMAR vision (20/30) (p = 0.01) compared with patients treated within 7 days. ROC analysis revealed that the optimal criterion of delay in IVMP initiation was ≤4 days, with a sensitivity and specificity of 71.4% and 76.9%, respectively. CONCLUSIONS: In this retrospective study of ON with AQP4 and MOG-IgG, even a 7-day delay in IVMP initiation was detrimental to vision. These results highlight the importance of early treatment for the long-term visual recovery in this group of patients. A prospective, multicenter study of the effects of timing of IVMP is currently underway. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that hyperacute treatment of AQP4 and MOG-ON with IVMP increases the chance for good visual recovery (20/20 vision) and that even a greater than 7-day delay in treatment is associated with a higher risk for poor visual recovery.
format Online
Article
Text
id pubmed-6624092
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-66240922019-07-26 Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Stiebel-Kalish, Hadas Hellmann, Mark Andrew Mimouni, Michael Paul, Friedemann Bialer, Omer Bach, Michael Lotan, Itay Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To investigate whether visual disability which is known to accumulate by poor recovery from optic neuritis (ON) attacks can be lessened by early treatment, we investigated whether the time from symptom onset to high-dose IV methylprednisolone (IVMP) affected visual recovery. METHODS: A retrospective study was performed in a consecutive cohort of patients following their first aquaporin-4 (AQP4)-IgG or myelin oligodendrocyte glycoprotein (MOG)-IgG-ON. Best-corrected visual acuity (BCVA) in ON eyes at 3 months (BCVA3mo) was correlated with time to IVMP (days). In cases of bilateral ON, 1 eye was randomly selected. RESULTS: A total of 29 of 37 patients had ON (27 AQP4-seropositive neuromyelitis optica spectrum disorder [NMOSD] and 9 MOG-IgG-ON), 2 of whom refused treatment. Of the 27 patients included, 10 presented later than 7 days from onset. The median BCVA3mo of patients treated >7 days was 20/100 (interquartile range 20/100–20/200). Patients treated >7 days had an OR of 5.50 (95% CI 0.88–34.46, p = 0.051) of failure to regain 0.0 logMAR vision (20/20) and an OR of 10.0 (95% CI 1.39–71.9) of failure to regain 0.2 logMAR vision (20/30) (p = 0.01) compared with patients treated within 7 days. ROC analysis revealed that the optimal criterion of delay in IVMP initiation was ≤4 days, with a sensitivity and specificity of 71.4% and 76.9%, respectively. CONCLUSIONS: In this retrospective study of ON with AQP4 and MOG-IgG, even a 7-day delay in IVMP initiation was detrimental to vision. These results highlight the importance of early treatment for the long-term visual recovery in this group of patients. A prospective, multicenter study of the effects of timing of IVMP is currently underway. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that hyperacute treatment of AQP4 and MOG-ON with IVMP increases the chance for good visual recovery (20/20 vision) and that even a greater than 7-day delay in treatment is associated with a higher risk for poor visual recovery. Lippincott Williams & Wilkins 2019-05-21 /pmc/articles/PMC6624092/ /pubmed/31355308 http://dx.doi.org/10.1212/NXI.0000000000000572 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Stiebel-Kalish, Hadas
Hellmann, Mark Andrew
Mimouni, Michael
Paul, Friedemann
Bialer, Omer
Bach, Michael
Lotan, Itay
Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
title Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
title_full Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
title_fullStr Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
title_full_unstemmed Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
title_short Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
title_sort does time equal vision in the acute treatment of a cohort of aqp4 and mog optic neuritis?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624092/
https://www.ncbi.nlm.nih.gov/pubmed/31355308
http://dx.doi.org/10.1212/NXI.0000000000000572
work_keys_str_mv AT stiebelkalishhadas doestimeequalvisionintheacutetreatmentofacohortofaqp4andmogopticneuritis
AT hellmannmarkandrew doestimeequalvisionintheacutetreatmentofacohortofaqp4andmogopticneuritis
AT mimounimichael doestimeequalvisionintheacutetreatmentofacohortofaqp4andmogopticneuritis
AT paulfriedemann doestimeequalvisionintheacutetreatmentofacohortofaqp4andmogopticneuritis
AT bialeromer doestimeequalvisionintheacutetreatmentofacohortofaqp4andmogopticneuritis
AT bachmichael doestimeequalvisionintheacutetreatmentofacohortofaqp4andmogopticneuritis
AT lotanitay doestimeequalvisionintheacutetreatmentofacohortofaqp4andmogopticneuritis